Respiratory Medicine
Volume 104, Issue 7 , Pages 1012-1019 , July 2010

Preselection of patients at risk for COPD by two simple screening questions

  • Harald Kögler

      Affiliations

    • Medical Science Department, Respiratory Medicine, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
    • ,
  • Norbert Metzdorf

      Affiliations

    • Medical Science Department, Respiratory Medicine, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
    • ,
  • Thomas Glaab

      Affiliations

    • Medical Science Department, Respiratory Medicine, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
    • ,
  • Tobias Welte

      Affiliations

    • Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
    • Department of Respiratory Medicine, Medizinische Hochschule Hannover, Carl Neuberg Strasse 1, Hannover D-30625, Germany
    • Corresponding Author InformationCorresponding author. Department of Respiratory Medicine, Medizinische Hochschule Hannover, Carl Neuberg Strasse 1, Hannover D-30625, Germany. Tel.: +49 511 532 3530; fax: +49 511 532 3353.

Received 13 October 2009 ,Accepted 10 January 2010.

References 

  1. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27:397–412
  2. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD study): a population-based prevalence survey. Lancet. 2007;370:741–750
  3. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1:1645–1648
  4. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. JAMA. 1994;272:1497–1505
  5. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States. Arch Intern Med. 2000;160:1683–1689
  6. Shahab L, Jarvis MJ, Brotton J, West R. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax. 2006;61:1043–1047
  7. Rennard S, Decramer M, Calverley PMA, Pride NB, Soriano JB, Vermeire PA, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of confronting COPD international survey. Eur Respir J. 2002;20:799–805
  8. Geldmacher H, Biller H, Herbst A, Urbanski K, Allison M, Buist AS, et al. The prevalence of chronic obstructive pulmonary disease (COPD) in Germany. Results of the BOLD study. Dtsch Med Wochenschr. 2008;133:2609–2614
  9. Price DB, Tinkelman DG, Halbert RJ, Nordyke RJ, Isonaka S, Nonikov D, et al. Symptom-based questionnaire for identifying COPD in smokers. Respiration. 2006;73:285–295
  10. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–555
  11. Celli BR, MacNee W, ATS/ERS Task Force . Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–946
  12. Lin K, Watkins B, Johnson T, Rodriguez JA, Barton MB. Screening for chronic obstructive pulmonary disease using spirometry: summary of the evidence for the U.S. preventive services task force. Ann Intern Med. 2008;148:535–543
  13. Kotz D, Nelemans P, van Schayck CP, Wesseling GJ. External validation of a COPD diagnostic questionnaire. Eur Respir J. 2008;31:298–303
  14. Humerfelt S, Eide GE, Kvåle G, Aarø LE, Gulsvik A. Effectiveness of postal smoking cessation advice: a randomized controlled trial in young men with reduced FEV1 and asbestos exposure. Eur Respir J. 1998;11:284–290
  15. Walters N, Coleman T. Comparison of the smoking behaviour and attitudes of smokers who attribute respiratory symptoms to smoking with those who do not. Br J Gen Pract. 2002;52:132–134
  16. Stratelis G, Mölstad S, Jakobsson P, Zetterström O. The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD. Scand J Prim Health Care. 2006;24:133–139
  17. Vollmer WM, Gíslason T, Burney P, Enright PL, Gulsvik A, Kocabas A, et al. for the BOLD Collaborative Research Group Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J. 2009;34:588–597
  18. O'Donnell DE, Laveneziana P, Ora J, Webb KA, Lam Y-M, Ofir D. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. Thorax. 2009;64:216–223
  19. Stratelis G, Jakobsson P, Molstad S, Zetterstrom O. Early detection of COPD in primary care: screening by invitation of smokers aged 40 to 55 years. Br J Gen Pract. 2004;54:201–206
  20. National Institute for Clinical Excellence . Chronic obstructive pulmonary disease: national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Appendix B: the cost effectiveness of opportunistic case finding in primary care. Thorax. 2004;59(Suppl.):175–190
  21. Britton M. The burden of COPD in the U.K.: results from the confronting COPD survey. Respir Med. 2003;97(Suppl. C):S71–S79
  22. Nowak D, Dietrich ES, Oberender P, Überla K, Reitberger U, Schlegel C, et al. Cost-of-illness study for the treatment of COPD in Germany. Pneumologie. 2004;58:837–844
  23. Sin DD, Stafinski T, Ng YC, Bell NR, Jacobs P. The impact of chronic obstructive pulmonary disease on work loss in the United States. Am J Respir Crit Care Med. 2002;165:704–707
  24. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 2006;27:188–207

PII: S0954-6111(10)00012-0

doi: 10.1016/j.rmed.2010.01.005

Respiratory Medicine
Volume 104, Issue 7 , Pages 1012-1019 , July 2010

Article Tools

* Image Usage & Resolution